JP2014516037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516037A5 JP2014516037A5 JP2014511554A JP2014511554A JP2014516037A5 JP 2014516037 A5 JP2014516037 A5 JP 2014516037A5 JP 2014511554 A JP2014511554 A JP 2014511554A JP 2014511554 A JP2014511554 A JP 2014511554A JP 2014516037 A5 JP2014516037 A5 JP 2014516037A5
- Authority
- JP
- Japan
- Prior art keywords
- aib
- exist
- ac5c
- ac4c
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 linker amino acid Chemical class 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 13
- 239000002253 acid Substances 0.000 claims 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 3
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 108010087791 pyroglutamylhistidine Proteins 0.000 claims 2
- SHCMCJLNUOZJOR-YXISZKLHSA-N (2s,3s,4s,5r,6r)-6-dodecyl-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical group CCCCCCCCCCCC[C@@]1(O)O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SHCMCJLNUOZJOR-YXISZKLHSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487640P | 2011-05-18 | 2011-05-18 | |
| US61/487,640 | 2011-05-18 | ||
| US201161543716P | 2011-10-05 | 2011-10-05 | |
| US61/543,716 | 2011-10-05 | ||
| PCT/US2012/038434 WO2012158965A2 (en) | 2011-05-18 | 2012-05-17 | Improved peptide pharmaceuticals for insulin resistance |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028560A Division JP6684396B2 (ja) | 2011-05-18 | 2017-02-19 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516037A JP2014516037A (ja) | 2014-07-07 |
| JP2014516037A5 true JP2014516037A5 (enExample) | 2015-07-09 |
| JP6284471B2 JP6284471B2 (ja) | 2018-02-28 |
Family
ID=47177642
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511554A Active JP6284471B2 (ja) | 2011-05-18 | 2012-05-17 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2017028560A Active JP6684396B2 (ja) | 2011-05-18 | 2017-02-19 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2019192289A Active JP7015610B2 (ja) | 2011-05-18 | 2019-10-21 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2022005872A Active JP7389150B2 (ja) | 2011-05-18 | 2022-01-18 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028560A Active JP6684396B2 (ja) | 2011-05-18 | 2017-02-19 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2019192289A Active JP7015610B2 (ja) | 2011-05-18 | 2019-10-21 | インスリン抵抗性のための改善されたペプチドの調合薬 |
| JP2022005872A Active JP7389150B2 (ja) | 2011-05-18 | 2022-01-18 | インスリン抵抗性のための改善されたペプチドの調合薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10471127B2 (enExample) |
| EP (1) | EP2710031B9 (enExample) |
| JP (4) | JP6284471B2 (enExample) |
| KR (5) | KR102011924B1 (enExample) |
| CN (2) | CN103732617A (enExample) |
| AU (1) | AU2012255119B2 (enExample) |
| BR (1) | BR112013029409B1 (enExample) |
| CA (2) | CA3134906A1 (enExample) |
| DK (1) | DK2710031T3 (enExample) |
| IL (1) | IL229373B (enExample) |
| MX (1) | MX344219B (enExample) |
| RU (1) | RU2602801C2 (enExample) |
| WO (1) | WO2012158965A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| CA3134906A1 (en) * | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| EA028929B1 (ru) | 2012-05-03 | 2018-01-31 | Зилэнд Фарма А/С | Аналоги глюкагоноподобного пептида-2 (glp-2) |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2922877B1 (en) * | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| WO2014081872A1 (en) | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| CN117582516A (zh) * | 2014-05-28 | 2024-02-23 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| KR102291020B1 (ko) | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| WO2016172183A1 (en) * | 2015-04-21 | 2016-10-27 | Ran Biotechnologies, Inc. | Novel fluorinated surfactants |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| FI3322437T3 (fi) | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| CN122440793A (zh) * | 2016-06-29 | 2026-07-24 | 韩美药品株式会社 | 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途 |
| KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
| IL271245B2 (en) | 2017-06-16 | 2023-10-01 | Zealand Pharma As | Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2 |
| CN108054388B (zh) * | 2017-12-26 | 2020-02-21 | 吉林大学 | 以h6p2w18/l-3-(2-萘基)-丙氨酸复合水基黏合剂为电极涂层的化学电池 |
| AU2019205905B2 (en) * | 2018-01-03 | 2024-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of NASH and other disorders |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| KR20240007251A (ko) | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| EP2292273A3 (en) * | 2001-10-10 | 2011-11-23 | BioGeneriX AG | Remodeling and glycoconjugation of peptides |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| US7776819B2 (en) | 2005-03-03 | 2010-08-17 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| CA2607566A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008060780A2 (en) * | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| CA2728284C (en) * | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| CA3134906A1 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| WO2014081872A1 (en) * | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| EP2922877B1 (en) * | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN117582516A (zh) | 2014-05-28 | 2024-02-23 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
-
2012
- 2012-05-17 CA CA3134906A patent/CA3134906A1/en active Pending
- 2012-05-17 CA CA2836574A patent/CA2836574C/en active Active
- 2012-05-17 CN CN201280035629.9A patent/CN103732617A/zh active Pending
- 2012-05-17 RU RU2013154047/04A patent/RU2602801C2/ru active
- 2012-05-17 KR KR1020137033668A patent/KR102011924B1/ko active Active
- 2012-05-17 BR BR112013029409-4A patent/BR112013029409B1/pt active IP Right Grant
- 2012-05-17 DK DK12785861.1T patent/DK2710031T3/en active
- 2012-05-17 KR KR1020217014931A patent/KR102497726B1/ko active Active
- 2012-05-17 KR KR1020237004115A patent/KR20230023059A/ko not_active Ceased
- 2012-05-17 KR KR1020247021588A patent/KR20240110072A/ko active Pending
- 2012-05-17 MX MX2013013395A patent/MX344219B/es active IP Right Grant
- 2012-05-17 CN CN202010611969.8A patent/CN111701028A/zh active Pending
- 2012-05-17 WO PCT/US2012/038434 patent/WO2012158965A2/en not_active Ceased
- 2012-05-17 KR KR1020197023482A patent/KR102255479B1/ko active Active
- 2012-05-17 JP JP2014511554A patent/JP6284471B2/ja active Active
- 2012-05-17 AU AU2012255119A patent/AU2012255119B2/en active Active
- 2012-05-17 EP EP12785861.1A patent/EP2710031B9/en active Active
- 2012-05-17 US US14/118,545 patent/US10471127B2/en active Active
-
2013
- 2013-11-11 IL IL229373A patent/IL229373B/en active IP Right Grant
-
2017
- 2017-02-19 JP JP2017028560A patent/JP6684396B2/ja active Active
-
2019
- 2019-10-21 JP JP2019192289A patent/JP7015610B2/ja active Active
-
2022
- 2022-01-18 JP JP2022005872A patent/JP7389150B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501204A5 (enExample) | ||
| JP2020073481A5 (enExample) | ||
| RU2013154047A (ru) | Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности | |
| CN102702330A (zh) | 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物 | |
| JP2012067099A5 (enExample) | ||
| JP2017535527A5 (enExample) | ||
| JP2011524420A5 (enExample) | ||
| JP7796636B2 (ja) | ヒトトランスフェリンレセプター結合ペプチド | |
| EP4199946B1 (en) | Crf2 receptor agonists and their use in therapy | |
| JPH08510261A (ja) | ポリマーを用いたビタミンｂ▲下１▼▲下２▼吸収系の増幅 | |
| JP2010529957A (ja) | 環状ペプチドｃｘｃｒ４アンタゴニスト | |
| JP2012518636A (ja) | 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート | |
| JPH0219397A (ja) | アルギニンバソプレシン拮抗剤の新規線形誘導体類 | |
| BR112015011478B1 (pt) | Produtos de peptídeo, seus usos e composição farmacêutica | |
| WO2024022465A1 (zh) | 一种人胰淀素多肽衍生物及其用途 | |
| CN101302246B (zh) | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 | |
| JPH0338600A (ja) | Ｖｉｐ同族体 | |
| ES2805536T3 (es) | Moléculas de neurotensina activadas y sus usos | |
| CN107592865B (zh) | 中和流感病毒的拟肽化合物 | |
| CA2405704C (en) | Bombesin analogs for treatment of cancer | |
| CN109069577A (zh) | Hiv进入的d-肽抑制剂以及使用方法 | |
| CN102250251A (zh) | 一种脑啡肽类似物的聚乙二醇化衍生物 | |
| JP2009528303A5 (enExample) | ||
| TWI858016B (zh) | 血球凝集素結合肽 | |
| JP2019520336A5 (enExample) |